[{"address1": "2000 Sierra Point Parkway", "address2": "Suite 501", "city": "Brisbane", "state": "CA", "zip": "94005", "country": "United States", "phone": "650 484 0899", "website": "https://dayonebio.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.", "fullTimeEmployees": 169, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jeremy  Bender M.B.A., Ph.D.", "age": 52, "title": "CEO, President & Director", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 1048400, "exercisedValue": 0, "unexercisedValue": 64677}, {"maxAge": 1, "name": "Dr. Samuel C. Blackman M.D., Ph.D.", "age": 54, "title": "Co-Founder and Head of R&D", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 740500, "exercisedValue": 0, "unexercisedValue": 21990}, {"maxAge": 1, "name": "Mr. Charles N. York II, M.B.A.", "age": 46, "title": "COO, CFO & Secretary", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 760000, "exercisedValue": 0, "unexercisedValue": 24599}, {"maxAge": 1, "name": "Mr. Adam  Dubow", "age": 56, "title": "General Counsel and Chief Compliance Officer", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 608200, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John  Stubenrauch Ph.D.", "title": "Chief Technology Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jaa  Roberson", "title": "Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Davy  Chiodin Ph.D., Pharm.D.", "title": "Chief Development Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Lauren  Merendino M.B.A.", "age": 47, "title": "Chief Commercial Officer", "yearBorn": 1976, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Elly  Barry M.D.", "title": "Chief Medical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 5, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 13.89, "open": 14.04, "dayLow": 13.86, "dayHigh": 14.57, "regularMarketPreviousClose": 13.89, "regularMarketOpen": 14.04, "regularMarketDayLow": 13.86, "regularMarketDayHigh": 14.57, "beta": -1.517, "forwardPE": -8.01105, "volume": 944720, "regularMarketVolume": 944720, "averageVolume": 984632, "averageVolume10days": 837360, "averageDailyVolume10Day": 837360, "bid": 14.45, "ask": 14.55, "bidSize": 300, "askSize": 100, "marketCap": 1425526912, "fiftyTwoWeekLow": 9.67, "fiftyTwoWeekHigh": 18.07, "priceToSalesTrailing12Months": 174.01451, "fiftyDayAverage": 14.2624, "twoHundredDayAverage": 14.41985, "currency": "USD", "enterpriseValue": 857316736, "floatShares": 60071155, "sharesOutstanding": 98312200, "sharesShort": 13573953, "sharesShortPriorMonth": 11524197, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.1381, "heldPercentInsiders": 0.19596, "heldPercentInstitutions": 0.8702, "shortRatio": 12.31, "shortPercentOfFloat": 0.16770001, "bookValue": 3.498, "priceToBook": 4.145226, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -167480000, "trailingEps": -1.94, "forwardEps": -1.81, "enterpriseToRevenue": 104.653, "enterpriseToEbitda": -2.985, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "DAWN", "underlyingSymbol": "DAWN", "shortName": "Day One Biopharmaceuticals, Inc", "longName": "Day One Biopharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1622122200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "a17405a3-1622-35cb-92a5-67defd12b1ed", "gmtOffSetMilliseconds": -14400000, "currentPrice": 14.5, "targetHighPrice": 54.0, "targetLowPrice": 24.0, "targetMeanPrice": 39.25, "targetMedianPrice": 40.0, "recommendationMean": 1.9, "recommendationKey": "buy", "numberOfAnalystOpinions": 8, "totalCash": 361865984, "totalCashPerShare": 4.123, "ebitda": -287168992, "totalDebt": 190000, "quickRatio": 3.959, "currentRatio": 4.089, "totalRevenue": 8192000, "debtToEquity": 0.062, "revenuePerShare": 0.095, "returnOnAssets": -0.42224, "returnOnEquity": -0.45711, "freeCashflow": -98021624, "operatingCashflow": -177294000, "grossMargins": 0.91370004, "operatingMargins": -14.01453, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]